Skip to main content
. 2017 Sep 12;2017:4934608. doi: 10.1155/2017/4934608

Figure 3.

Figure 3

5-year disease-free survival rate analysis of TNBC patients treated with anthracycline-based adjuvant chemotherapy. At 5 years of follow up, the TNBC patients were grouped according to their PITX2 DNA methylation value with a cut-off of 6.35 percent methylation ratio (PMR). Low PITX2 DNA methylation status (n = 18) shows a poor disease-free survival rate at 5 years (35.6%); high PITX2 DNA methylation status (n = 38) is associated at 5-year observation time with favorable disease-free survival (83.5%). (p values: log-rank test, p = 0.006; Wilcoxon test, p = 0.003) [66].